Scott L. Friedman
0000-0003-1178-6195
Publication & Citation Trends
Publications
0 total
Anti-FAP CAR T cells produced in vivo reduce fibrosis and restore liver homeostasis in metabolic dysfunction-associated steatohepatitis.
Cited by 4
Semantic Scholar
Advances in Extracellular Matrix-Associated Diagnostics and Therapeutics
Cited by 17
Semantic Scholar
Cannabinoid Receptor 2 Activating Antibodies: A Promising Therapeutic Strategy for Macrophage-Driven Fibro-Inflammatory Diseases
Cited by 1
Semantic Scholar
Depletion of tumor-reactive HSCs reveals their significance during different stages of liver metastasis OA
Cited by 1
Semantic Scholar
Resolvin D1-mediated cellular crosstalk protects against MASH
Cited by 5
Semantic Scholar
Antifibrotic therapies for metabolic dysfunction-associated steatotic liver disease
Cited by 21
Semantic Scholar
Mannose reduces fructose metabolism and reverses MASH in human liver slices and murine models in vivo
Cited by 1
Semantic Scholar
Chimeric Antigen Receptor (CAR) T-cell Therapy: Engineering Immune Cells To Treat Liver Diseases.
Cited by 14
Semantic Scholar
Conditional deletion of CEACAM1 causes hepatic stellate cell activation OA
Cited by 1
Semantic Scholar
Research Topics
Liver Disease Diagnosis and Treatment
(340)
Liver physiology and pathology
(242)
Kruppel-like factors research
(72)
Liver Disease and Transplantation
(71)
Liver Diseases and Immunity
(48)
Affiliations
Roche (Switzerland)
AT&T (United States)
Cincinnati Children's Hospital Medical Center
San Francisco General Hospital
New York City Fire Department